TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Dianthus Therapeutics
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Dianthus Therapeutics reported successful Phase 2 trial results for claseprubart in generalized Myasthenia Gravis, demonstrating promising treatment effects and announcing plans for a Phase 3 trial in 2026.

Insights
DNTH   positive

Presented successful Phase 2 trial data, demonstrated treatment potential, and outlined clear plans for Phase 3 clinical trial with promising preclinical insights